DGAP-News: STRATEC reports on first nine months of 2013
(firmenpresse) - DGAP-News: STRATEC Biomedical AG / Key word(s): Quarter
Results/Interim Report
STRATEC reports on first nine months of 2013
30.10.2013 / 07:42
---------------------------------------------------------------------
STRATEC reports on first nine months of 2013
- Sales of EUR 90.4 million in 9M/2013 (+7.2%; 9M/2012: EUR 84.3 million*)
- EBIT margin of 16.2% in Q3/2013 (Q3/2012: 13.4%)
- EBIT margin of 14.8% in 9M/2013 (9M/2012: 15.8%*)
- Earnings per share of EUR 0.90 in 9M/2013 (-3.2%; 9M/2012: EUR 0.93)
- Financial guidance confirmed
Birkenfeld, October 30, 2013
STRATEC Biomedical AG (Frankfurt: SBS; Prime Standard, TecDAX) today
announced its results for the period from January 1, 2013 to September 30,
2013 upon the publication of its Interim Report as of September 30, 2013.
Key figures (EUR 000s) 01.01.-09.30.2013 01.01.-09.30.2012* Change* 2012 figure adjusted for a one-off item of EUR 3.3 million due to an
Sales 90,418 84,316 + 7.2%
EBIT 13,361 13,357 + 0.0%
EBIT margin (%) 14.8 15.8 --
Consolidated net income 10,517 10,865 - 3.2%
Earnings per share (EUR) 0.90 0.93 - 3.2%
income-neutral reclassification from unfinished services and prepayments
received upon the write-down of a development project. On an unadjusted
basis, sales for the first nine months of 2012 amounted to EUR 87.6 million
and the corresponding EBIT margin amounted to 15.3%.
Financial performance
STRATEC generated moderate sales growth in the first nine months of 2013,
despite temporary restrictions to day-to-day operations caused by flood
damage in June. Net of a one-off income-neutral reclassification in the
previous year, sales rose to EUR 90.4 million, up 7.2% on the first nine
months of 2012. Sales for the third quarter showed a year-on-year increase
of 5.8% to EUR 31.0 million.
The EBIT margin for the first nine-months amounted to 14.8%, compared to
15.8% in the equivalent period in 2012. In H1 2012 we saw strong business
performance with service parts resulting in an EBIT margin of 17.1%, before
an uncharacteristically sharp decline in H2 2012. Since the beginning of
2013, demand has continued to improve in this segment and order volatility
has slightly declined. Consequently, the share of sales from service parts
has recovered to a higher level compared to an extraordinary fourth quarter
2012. The EBIT margin for the third quarter alone amounted to 16.2%,
compared to 13.4% for Q3 2012, driven mainly by this recovery in service
parts year-on-year.
Earnings per share amounted to EUR 0.90 in the period under report,
compared with EUR 0.93 in the previous year.
Project development
The systems already established on the market have generated moderate
growth rates. The systems launched onto the market in 2013 so far only
account for an immaterial share of the current sales growth. We expect
their share of sales to rise consistently over the coming quarters.
Moreover, the market launch of a new system is due in the fourth quarter.
Furthermore, two further market launches and analyzer system approvals are
set to follow in 2014.
Alongside a major new development and supply agreement signed in the first
quarter of 2013, a further contract is now in the final agreement stage.
Both projects are expected to make notable contributions to STRATEC's sales
growth from the 2015 and 2016 financial years respectively.
Other developments
On July 12, 2013, STRATEC reported the termination by a customer of a
development and supply agreement. Compensation for STRATEC is being
negotiated with the customer. At present, no more precise details can be
provided as to the nature, amount or timing of such compensation. Neither
the other projects with this partner nor projects with other partners have
been affected by this contract termination.
Developments in staff totals
Including temporary employees, the STRATEC Group had a total of 544
employees as of September 30, 2013 (September 30, 2012: 524). The company's
workforce thus grew by a further 17 employees compared with December 31,
2012.
Outlook and company forecast
The current company forecast published on July 12, 2013 remains valid.
Accordingly, STRATEC expects to generate sales of between EUR 127 million
and EUR 138 million with an EBIT margin of 14.0% to 15.5% in the 2013
financial year. Average annual sales growth of 8% to 12% based on the
figures for the 2013 financial year is then expected in subsequent years
until 2017. Profitability is expected to improve slightly, albeit in
proportion with the number and scale of new development projects and thus
with the investments involved.
Planning reliability in the global diagnostics industry is currently
affected by a number of uncertainties, such as government savings measures,
high unemployment in important market regions, and healthcare system
reforms. Particularly the healthcare reforms in the USA will not be without
consequences. According to statements made by several partners, the
negative implications of the persistently high pressure on prices expected
at laboratories and hospitals are likely to be offset by the increase in
test volumes also expected due to the marked rise in the number of people
insured.
Our ability to forecast developments continues to be impeded by several
other external factors, such as capacity utilization rates at installed
systems, the timing of further market launches, the planned production
launches for new systems, further consolidation in the IVD market, and
macroeconomic market factors.
Further details can be found in our Interim Report as of September 30, 2013
published at www.stratec.com>STRATEC Group>Investors>Financial
Reports.
About STRATEC
STRATEC Biomedical AG (www.stratec.com) designs and manufactures fully
automated analyzer systems for its partners in the fields of clinical
diagnostics and biotechnology. These partners market such systems, in
general together with their own reagents, as system solutions to
laboratories, blood banks and research institutes around the world. The
company develops its products on the basis of its own patented
technologies.
Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard
segment of the Frankfurt Stock Exchange and are listed in the TecDAX select
index of the German Stock Exchange.
Further information can be obtained from:
STRATEC Biomedical AG
AndréLoy, Investor Relations
Gewerbestr. 37, 75217 Birkenfeld
Germany
Tel: +49 7082 7916-190
Fax: +49 7082 7916-999
ir(at)stratec.com
www.stratec.com
End of Corporate News
---------------------------------------------------------------------
30.10.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: STRATEC Biomedical AG
Gewerbestr. 37
75217 BirkenfeldGermany
Phone: +49 (0)7082 7916 0
Fax: +49 (0)7082 7916 999
E-mail: info(at)stratec.com
Internet: www.stratec.com
ISIN: DE0007289001
WKN: 728900
Indices: TecDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
236771 30.10.2013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: EquityStory
" alt="Intelimax Updates Membership Growth Disclosure
Datum: 30.10.2013 - 07:42 Uhr
Sprache: Deutsch
News-ID 310645
Anzahl Zeichen: 10834
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 259 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: STRATEC reports on first nine months of 2013"
steht unter der journalistisch-redaktionellen Verantwortung von
STRATEC Biomedical AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
